INSL4 and prostate cancer: Decreased levels of hsa-miR-494-3p, hsa-miR-3128, hsa-miR-8084 and therefore likely to increase levels of targets HIF1A, AVRP1A, NHS, INSL4 may be novel biomarker candidates for early-stage diagnosis and treatment of prostate cancer.